Paper40286161
Anticancer Activity and Safety Profile of Novel 1-(4-Fluorophenoxyacetyl)-4-substituted Thio/Semicarbazide Derivatives.
Kozyra P and 7 others. Molecules, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Anticancer Activity and Safety Profile of Novel 1-(4-Fluorophenoxyacetyl)-4-substituted Thio/Semicarbazide Derivatives. Papers, record 40286161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40286161
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anticancer Activity and Safety Profile of Novel 1-(4-Fluorophenoxyacetyl)-4-substituted Thio/Semicarbazide Derivatives.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Semicarbazides | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Molecular Docking Simulation | |
| Structure-Activity Relationship | |
| Molecular Structure | |
| Male | |
| Cell Proliferation |
Source PubMed
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 2 | 26560244 | Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression. | PLoS One | 2015 | https://conductscience.org/library/papers/26560244 | PubMed |
| 3 | 11259830 | Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. | Adv Drug Deliv Rev | 2001 | https://conductscience.org/library/papers/11259830 | PubMed |
| 4 | 34301763 | ATR/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G2-M Checkpoint Maintenance. | Cancer Res | 2021 | https://conductscience.org/library/papers/34301763 | PubMed |
| 5 | 37175436 | FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37175436 | PubMed |
| 6 | 27218427 | A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. | ChemMedChem | 2016 | https://conductscience.org/library/papers/27218427 | PubMed |
| 7 | 18197348 | Fluorine in medicinal chemistry. | Chem Soc Rev | 2008 | https://conductscience.org/library/papers/18197348 | PubMed |
| 8 | 26200936 | Applications of Fluorine in Medicinal Chemistry. | J Med Chem | 2015 | https://conductscience.org/library/papers/26200936 | PubMed |
| 9 | 36313628 | The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36313628 | PubMed |
| 10 | 25363687 | Novel thiosemicarbazides induced apoptosis in human MCF-7 breast cancer cells via JNK signaling. | J Enzyme Inhib Med Chem | 2015 | https://conductscience.org/library/papers/25363687 | PubMed |
| 11 | 28067251 | Analgesic and Anti-Inflammatory Effects of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models of the Mouse. | Sci Rep | 2017 | https://conductscience.org/library/papers/28067251 | PubMed |
| 12 | 26501210 | Pharmacological effects of primaquine ureas and semicarbazides on the central nervous system in mice and antimalarial activity in vitro. | Fundam Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26501210 | PubMed |
| 13 | 24821317 | Design, synthesis and biological evaluation of novel thiosemicarbazide analogues as potent anticonvulsant agents. | Bioorg Chem | 2014 | https://conductscience.org/library/papers/24821317 | PubMed |
| 14 | 32069994 | 2,4-Dichlorophenoxyacetic Thiosemicarbazides as a New Class of Compounds Against Stomach Cancer Potentially Intercalating with DNA. | Biomolecules | 2020 | https://conductscience.org/library/papers/32069994 | PubMed |
| 15 | 22405290 | Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants. | Eur J Med Chem | 2012 | https://conductscience.org/library/papers/22405290 | PubMed |
| 16 | 32596789 | Comparative biological study between quinazolinyl-triazinyl semicarbazide and thiosemicarbazide hybrid derivatives. | Mol Divers | 2021 | https://conductscience.org/library/papers/32596789 | PubMed |
| 17 | 35204651 | Potential Anticancer Agents against Melanoma Cells Based on an As-Synthesized Thiosemicarbazide Derivative. | Biomolecules | 2022 | https://conductscience.org/library/papers/35204651 | PubMed |
| 18 | 36012142 | Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36012142 | PubMed |
| 19 | 29131470 | Synthesis of some novel pyridine compounds containing bis-1,2,4-triazole/thiosemicarbazide moiety and investigation of their antioxidant properties, carbonic anhydrase, and acetylcholinesterase enzymes inhibition profiles. | J Biochem Mol Toxicol | 2018 | https://conductscience.org/library/papers/29131470 | PubMed |
| 20 | 12036371 | Molecular properties that influence the oral bioavailability of drug candidates. | J Med Chem | 2002 | https://conductscience.org/library/papers/12036371 | PubMed |
| 21 | 32811412 | Thiosemicarbazides: Updates on Antivirals Strategy. | Mini Rev Med Chem | 2020 | https://conductscience.org/library/papers/32811412 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41901229 | Synthesis and Development of 3-((2,4-Difluorophenyl)Amino)Propanoic Acid Derivatives as an Antiproliferative Medicinal Chemistry Scaffold Targeting Growth Factor Receptors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41901229 | PubMed |
| 41784864 | New molecules candidates with a semicarbazide scaffold - anticancer potential in view of research on their physicochemical properties, antioxidant activity, and preliminary biological activity. | Pharmacol Rep | 2026 | https://conductscience.org/library/papers/41784864 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TOP2A | 7153 | PubTator's text mining | https://conductscience.org/library/genes/7153 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40286161
GET https://conductscience.org/api/papers/v1/40286161/references?page=2